home / stock / cybn:cc / cybn:cc news

CYBN:CC News and Press, CYBIN INC. From 12/05/23

Stock Information
Company Name: CYBIN INC.
Stock Symbol: CYBN:CC
Market: AQNC
Menu
CYBN:CC CYBN:CC Quote CYBN:CC Short CYBN:CC News CYBN:CC Articles CYBN:CC Message Board
Get CYBN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Four Poster Presentations at the 2023 ACNP Annual Meeting

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options. The company today announced the presentation of four posters at the American...
CYBN:CC - Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

- Poster presentations highlight data across Cybin’s CYB003 and deuterated DMT clinical programs, as well as preclinical development programs - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biop...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Topline Safety, Efficacy Data for MDD Study

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released positive phase 2 topline safety and efficacy data for CYB003, its proprietary...

CYBN:CC - Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose - - Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that it will discuss its topline phase 2 safety and efficacy dat...

CYBN:CC - Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

- Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer - - Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Prof...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be hosting a research and development briefing on Nov. 30, 2023, at 10 a.m. ET in New...
CYBN:CC - Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a ...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023. The event, hosted ...

CYBN:CC - Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today an...
Previous 10 Next 10